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T he purpose of this article is to present the design forthe National Emphysema Treatment Trial (NETT).
This trial is a collaborative effort of 17 clinical centers,
a study coordinating/statistical center, the National
Heart, Lung, and Blood Institute (NHLBI), and the
Health Care Financing Administration (HCFA). The
study protocol and procedures were finalized in 1997-
1998. Screening began in October 1997 and random-
ization began in January 1998.
Overview
Terminology. Emphysema is a condition of the lung
characterized by abnormal permanent enlargement of air
spaces distal to the terminal bronchiole, accompanied by
destruction of their walls in the absence of obvious
fibrosis.1 The cardinal physiologic defect in emphysema
is a decrease in elastic recoil. This decrease in elastic
recoil results in the principal physiologic abnormalities
of emphysema: decreased maximum expiratory air flow,
hyperinflation, and air trapping. The destruction of the
alveolar-capillary membrane surface leads to a reduction
in diffusing capacity. Emphysema is usually the result of
cigarette smoking, although it can occur occasionally
without this exposure, notably in a 1-antitrypsin defi-
ciency. It is a chronic progressive disorder that ultimate-
ly leads to disability and early death. Emphysema is esti-
mated to be present in 2 million adults in the United
States and, along with other forms of chronic obstructive
pulmonary disease (COPD), accounts for more than
90,000 deaths annually.2
Present state of treatment for emphysema.
Guidelines for the diagnosis and management of
emphysema have been recently promulgated.1,3 The
goals of therapy in emphysema, as in other forms of
COPD, are to halt the progressive decline in lung func-
tion, prevent and shorten exacerbations of the disease,
improve exercise capacity and quality of life, and pro-
long survival. The only treatment that has been shown
to alter the rate of progression of COPD is cessation of
smoking.4 Influenza immunization and pneumococcal
vaccination are recommended for prevention of inter-
current life-threatening infections.5,6 As a rule, exacer-
bations of disease are treated with antibiotics, steroids,
and bronchodilators. Although these interventions are
believed to shorten the duration of individual episodes
and minimize symptoms, there is little evidence that
they either alter the natural history of the disease or
reduce mortality.7,8 Bronchodilators improve lung func-
tion, exercise capacity, and quality of life in patients
with COPD but are of limited benefit to patients with-
out reversible airway disease.9 Pulmonary rehabilita-
tion, including aerobic exercise conditioning, educa-
tion, and psychosocial support, improves exercise
capacity in patients with COPD and may reduce the rate
of hospitalization.10-13
Long-term domiciliary oxygen therapy in hypoxemic
patients is the only treatment for COPD that has been
documented to decrease mortality rates.14,15 Adjunctive
forms of therapy, such as mucolytics to control respira-
tory secretions or narcotics to reduce the sensation of
dyspnea, have been used in selected patients with
COPD.16 In patients with a 1-protease inhibitor defi-
ciency, protective serum levels of the enzyme may be
restored by regular infusions of exogenous a 1-protease
inhibitor,17 but it is unclear whether restoring serum
levels protects against progression of the disease or pro-
longs survival.11 In patients with far-advanced COPD,
single or double lung transplantation has been used as a
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last resort, but this option is limited by the small num-
ber of donor organs.
Surgery for emphysema. The failure of medical
treatment to produce prolonged improvement of symp-
toms has prompted the introduction of various surgical
procedures over the past 90 years in an attempt to
improve symptoms in patients with emphysema.18 On
the basis of the premise that patients with severe
emphysema have lungs that have become too large rel-
ative to the size of their chests, several different opera-
tive procedures, including pneumoperitoneum, phrenic
nerve paralysis, thoracoplasty, or excision of costal car-
tilage combined with a partial sternotomy, have been
tried in uncontrolled series of patients.18 Other opera-
tions have included denervation of the lungs, stabiliza-
tion and fixation of the trachea, and procedures to cor-
rect gastroesophageal reflux disease. These procedures
produced minimal or no benefit to the patients.18
In 1957, Brantigan and Mueller19 reported the surgi-
cal excision of lung tissue to reduce the volume of the
hyperinflated lung parenchyma, so-called “lung vol-
ume reduction surgery (LVRS).” Although 75% of
patients reported clinical improvement, the lack of
objective documentation for benefit from the procedure
and an operative mortality of 18% prevented wide-
spread acceptance of the procedure.
In more recent years, the concept of reducing lung
volume surgically in emphysema has been re-explored.
In 1991, Wakabayashi and colleagues20 reported using
the carbon dioxide laser to shrink bullous areas of the
lung via a thoracoscopic approach. In 1995, Cooper
and associates21 reported a modification of Brantigan’s
volume reduction operation, in which lung tissue was
resected from both lungs via a median sternotomy. In
the initial 20 cases reported, there was no operative
mortality and the operation produced an 82% mean
increase in the forced expiratory volume in 1 second
and significant improvement in the distance walked in
6 minutes. Moreover, many patients were able to dis-
continue supplemental oxygen. Subsequent random-
ized prospective studies suggested that the results with
stapled resection were superior to those obtained by
laser ablation22 and that bilateral resection was superi-
or to unilateral resection.23
Existing data on LVRS. A number of investigators
have reported their results after bilateral LVRS.23-29
From this combined experience, 738 patients showed a
61% mean improvement in the forced expiratory vol-
ume in 1 second and a 45.7% mean improvement in the
distance walked in 6 minutes; 62% of the oxygen-
dependent patients became oxygen-independent. The
operative mortality in these series ranged from 2.5% to
10%, and the mean length of hospital stay ranged from
10.9 to 17 days.
The favorable results reported in the above series
contrasted with data collected from 722 Medicare
claims that used the LVRS billing code between
October 1995 and January 1996.30 Mortality rates 3
and 12 months after the operation were 14.4% and
23%, respectively. For these patients, acute care hospi-
talizations and use of long-term care and rehabilitation
services were greater after as compared with before the
operation (304 stays for 160 patients after the operation
vs 197 stays for 123 patients before the operation; the
in-patient stay associated with LVRS was excluded
from these analyses). Average days hospitalized was
greater after than before the operation.
During development of the NETT protocol, the his-
torical experience with LVRS at the original 18 clinical
centers was reviewed by the Coordinating Center at the
request of the NETT Steering Committee. The centers
collectively reported 1741 patients who had undergone
LVRS by bilateral, unilateral, laser, and excision pro-
cedures. The number of patients per center ranged
between 13 and 371. Data were requested on baseline
prognostic variables (such as age, sex, and pulmonary
function tests), pulmonary function tests done 6
months after the operation, the 6-minute walk test, vital
status, and duration of survival. Investigators were also
asked to make an assessment for each patient of
whether the patient had benefited from the LVRS; each
investigator could use his or her discretion regarding
the criteria for the assessment of benefit or no benefit.
Analyses were conducted on all 1741 patients regard-
less of the type of LVRS procedure. 
The analyses showed that considerable historical data
were missing, creating difficulty in drawing statistical
inferences. For example, only 25% of the 1741 patients
had sufficient baseline and follow-up data on prognos-
tic variables for meaningful analyses. Inferences from
the historical data were compromised not only by the
missing values but also by the potential for strong bias-
es in follow-up and functional assessment. In general,
investigators seemed inclined to attribute benefit to the
procedure, as seen in the requested subjective assess-
ment of benefit or no benefit. Logistic regression tech-
niques were used on one half of the historical data set
to identify baseline covariates predictive of benefit. The
other half of the data set was used to determine the sen-
sitivity and specificity of the covariates identified as
predictive of benefit. The best sensitivity and specifici-
ty for prediction of benefit were approximately 62%
and 64%, respectively. In summary, the historical data
did not provide convincing evidence for efficacy or
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reliable characterization of a subset of patients likely to
benefit from LVRS.
Rationale for the trial. As indicated above, pub-
lished reports on LVRS deal with relatively small num-
bers of selected patients without long-term follow-up
or comprehensive assessment of risks, benefits, and
costs. In these reports, there is considerable variability
in baseline assessments, types of operations performed,
procedures involved in preoperative, intraoperative,
and postoperative care, and type and completeness of
follow-up evaluations. In addition, although selection
criteria were not standardized, only a small proportion
of the patients who were evaluated for LVRS actually
underwent the procedure. The natural history of these
patients, with or without surgery, has not been carefully
monitored.
A number of medical centers across the United States
tried to reproduce the initial reports of success with
LVRS. At several of these sites, mortality rates were
inordinately high, raising questions about the risk/ben-
efit ratio of medical therapy versus medical therapy
plus surgical intervention. Among the questions were
these: How long would the benefit from surgery last?
What is the optimal technique for performing the pro-
cedure? What are the clinical outcomes beyond the first
few postoperative months? Can a subset of patients
who would benefit from the procedure be defined?
Thus key questions remain about whether the bene-
fits of LVRS outweigh the associated risks and costs
and about issues of efficacy, safety, and patient selec-
tion. These questions are particularly pertinent for this
group of individuals, who have advanced emphysema-
tous lung disease and who are willing to try any new
form of treatment that has the potential of relieving
their considerable discomfort in breathing.
Outcome measures
Primary measures. The 2 primary outcome mea-
sures chosen for the NETT are survival and maximum
exercise capacity. Although many investigators favored
palliation (measured by dyspnea scores, quality of life,
and exercise capacity) as a more appropriate primary
outcome measure than mortality, survival was chosen
as the primary outcome for 3 reasons: (1) It is clinical-
ly significant because patients with severe emphysema
have a high mortality rate; (2) it can be objectively
assessed and is easily quantified; and (3) a statistical
design for differences in survival ensures a sufficient
number of participants for other important outcome
measures.
The other primary measure of outcome, the maximum
exercise capacity, was chosen as a measure of integrat-
ed cardiopulmonary and physical performance. It is
determined by maximal, incremental, symptom-limited
exercise with the patient using a cycle ergometer. This
test affords several advantages over the 6-minute walk
test: it is easier to standardize, it is more reproducible, it
is not difficult to administer, and it entails less of a
learning effect. Exercise capacity was favored over pul-
monary function tests as a primary measure of outcome
because studies to date have not documented a consis-
tent relationship between improvement in functional
status and changes in pulmonary function, particularly
in patients treated medically.
Secondary measures. The following secondary
measures will be used in the assessment of outcomes.
Quality of life and related disease-specific symptoms.
Quality of life and related disease-specific symptoms,
possibly the most important outcome measures to the
patients participating in the trial, will be measured both
by general and disease-specific instruments. General
quality of life will be assessed by the Medical
Outcomes Study 36-Item Short Form (SF-36)31 and the
utility weighted Quality of Well-Being Scale (QWB).32
The SF-36 is widely used; its inclusion in the NETT
battery will allow comparison of results from NETT
with results from other studies. The QWB scale is
widely used to provide an estimate of Quality Adjusted
Life Years (QALYs), an important measure for the cost
effectiveness analysis. Disease-specific quality of life
will be assessed with the St George’s Respiratory
Questionnaire (SGRQ),33 an instrument that has been
developed and validated in patients with COPD. The
University of California, San Diego Shortness of
Breath Questionnaire (SOBQ),34 and the modified
Borg Scale for perceived dyspnea35,36 will be used to
assess dyspnea, the most important symptom of chron-
ic lung disease. The SOBQ is sensitive to small
changes in perceived breathlessness and provides infor-
mation about breathlessness with daily activities that
can be helpful in the clinical evaluation of patients and
their management in rehabilitation. The modified Borg
Scale is used at the start and close of the 6-minute walk
test and maximum exercise testing to obtain ratings of
perceived dyspnea and muscle fatigue before and after
exercise. The SF-36, QWB, SGRQ, and SOBQ are
self-administered scales that can be completed within
60 minutes.
Cost effectiveness analysis. Cost effectiveness will be
analyzed with incremental QALYs used as the denom-
inator and incremental costs in the numerator. Costs
will include resources consumed during the course of
care; values or prices will be assigned to each resource.
Costs of therapy include medical and surgical care,
The Journal of Thoracic and
Cardiovascular Surgery
Volume 118, Number 3
NETT Research Group   521
non-medical care related to the treatment, family or
friends’ time (valued to dollars) for caring for the
patient, and the value of the patient’s time obtaining
treatment. The analysis will be completed both from
this general societal perspective and from the Medicare
perspective. The latter includes only the costs that
Medicare covers. Details about the cost effectiveness
analysis will be published elsewhere.
Pulmonary function and gas exchange. Pulmonary
function and gas exchange will be assessed in all patients
at the time of the initial evaluation and at all follow-up
visits. Tests will include spirometry, plethysmographic
determination of the functional residual capacity, the sin-
gle-breath diffusing capacity, arterial blood gases at rest,
and the maximal inspiratory and expiratory mouth pres-
sures. Selected clinics will assess pulmonary mechanics
in greater detail, including determinations of lung elastic
recoil pressures, flow-volume relationships, pulmonary
resistance, respiratory muscle function, and arterial
blood gases during maximum exercise.
Radiologic studies. Radiologic studies will include
standard chest radiographs, volumetric and high-reso-
lution computed tomographic scans, and nuclear perfu-
sion scans. Chest radiographs and computed tomo-
graphic scans will be performed at the time of initial
evaluation and at 2 follow-up visits; perfusion scans
will be performed at the initial evaluation only.
Computed tomographic scans will be used to verify the
presence of emphysema and to assess the distribution
and severity of the disease.
Oxygen requirement. The requirement of patients for
supplemental oxygen will be assessed on entry into the
study and in follow-up. This will be done by adjusting
the oxygen concentration of inspired air to maintain the
oxygen saturation of arterial blood at greater than 90%
while the patient walks on a treadmill, at level grade, at
1 mile per hour.
Six-minute walk distance. This exercise parameter is
included largely because of its widespread use by
investigators who have previously reported on the
results of LVRS. However, it has been designated as a
secondary, rather than a primary, measure of outcome
because the test is difficult to standardize.37 The test
will be performed initially and during follow-up.
Cardiovascular measures. All patients will undergo
echocardiographic studies during the initial assess-
ment. All patients with evidence of abnormally high
pulmonary arterial pressures will undergo right heart
catheterization as part of their evaluation for inclusion
in the trial. Patients with pulmonary hypertension are
ineligible because of the possibility of increased sur-
gical risk. All patients will undergo at least 1 follow-
up echocardiographic study. At selected clinics,
patients will undergo initial and follow-up right heart
catheterization.
Attention and psychomotor functioning. The Trail
Making Test38,39 will be used at baseline and annual
follow-up visits to evaluate changes in cognitive abili-
ty or performance over time. The test is included
because it is informative, simple to administer, and sen-
sitive to hypoxia.
Study design
The NETT is a randomized clinical trial that com-
pares medical therapy for emphysema with medical
therapy plus LVRS. The only patients who can enroll
are Medicare beneficiaries or those whose insurance
carrier is willing to cover the costs of participation in
the trial.
The trial has 3 components:
1. The main protocol, which involves all enrolled
patients at all participating clinical centers and
addresses the primary and secondary objectives of
the NETT
2. Several substudies, performed only at selected cen-
ters and involving only patients enrolled at those cen-
ters, addressing specific issues related to LVRS
3. Ancillary studies, which are not part of the main
NETT protocol, but either involve patients partici-
pating in the NETT or take advantage of information
or materials obtained during the course of the NETT.
These studies require approval from the NETT
Steering Committee and separate consent from the
patients.
Patient participation. The recruitment goal for the
trial is 2500 patients; 6% of these are expected to be of
minority background and 30% are expected to be
female. The study duration is set at 4.5 years with a 6-
month close-out period.
Patients with moderate to severe emphysema, who
have been nonsmokers for 6 months before randomiza-
tion and are judged to be free of other diseases, dis-
abilities, or circumstances likely to interfere with ther-
apy and/or data collection for the duration of the trial,
will be offered the opportunity to enroll in the NETT.
At all clinical centers, participants, after enrollment
and pulmonary rehabilitation, will be randomized to a
program of medical therapy or to a program of medical
therapy plus LVRS in a 1:1 ratio. At those clinical cen-
ters that offer LVRS by both median sternotomy and
video-assisted thoracoscopic surgical (VATS) proce-
dures, those randomized to the surgical arm will partic-
ipate in a second randomization between the 2 surgical
approaches, also in a 1:1 ratio.
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Screening process. Patients may either self-refer for
evaluation at a NETT clinical center or be referred by a
physician. Patients or their physicians, or both, will be
asked to provide a brief history, chest radiograph, elec-
trocardiographic report, and the results of spirometry.
These data will be reviewed at the clinical center.
Those without identifiable contraindication will be
invited to the clinical center for evaluation and testing.
All patients who initiate screening at a NETT clinic are
included in the NETT registry. Patients who are found
to be ineligible for randomization remain in the registry
and will be observed for vital status.
Patients invited for further evaluation will undertake
a process designed to (1) establish eligibility to be
enrolled in the NETT and (2) provide the baseline
assessments that will serve as reference data for the
duration of the trial. The evaluation process is outlined
in Table I and the post-rehabilitation assessment in
Table II.
The patient selection criteria for the NETT were for-
mulated to achieve 2 broad goals:
1. Enrollment of patients with emphysema; patients
with either heterogeneous or homogeneous emphy-
sema will be included. 
2. Exclusion of patients at high risk for perioperative
morbidity or mortality, as well as patients unlikely to
be able to complete the trial.
Inclusion criteria. The inclusion criteria were
designed to enroll patients with severe obstructive lung
disease primarily due to emphysema. The criteria were
formulated to include patients with a diverse distribu-
tion of emphysema to examine the effect of the
anatomic distribution of disease on the response to
therapy. The inclusion criteria include (1) radiographic
evidence of bilateral emphysema, (2) studies demon-
strating severe air-flow obstruction and hyperinflation,
and (3) participation in pulmonary rehabilitation with
the attainment of preset performance goals (Table III).
Exclusion criteria. Exclusion criteria were formulat-
ed with the goal of excluding certain patients with
emphysema: (1) characteristics that place them at high
risk for perioperative morbidity or mortality, (2) disease
believed to be unsuitable for LVRS, and (3) medical con-
ditions or other circumstances that make it likely that the
patient would be unable to complete the trial (Table IV).
The exclusionary criteria relating to cardiologic issues
are based on the work of Goldman and associates.40
Treatments in the NETT
Medical therapy. Medical therapy will closely fol-
low the guidelines proposed by the American Thoracic
Society.1 The NETT pulmonary physician will provide
recommendations for medical therapy for each partici-
pant in the trial. Overall responsibility for medical man-
agement will remain with the patient’s primary care
physician. Medical treatment will include the following:
Smoking cessation. Although eligibility for participa-
tion in NETT requires smoking cessation for at least 6
months before randomization and biochemical valida-
tion at the time of screening, it is anticipated that some
participants may resume smoking during the NETT.
Relapses will be treated in line with the AHCPR guide-
lines, including counseling, referral to group programs,
and nicotine replacement therapy.
Regular inhaled bronchodilators. In general, treat-
ment will include both an anticholinergic bronchodila-
tor and a b 2-agonist. The preferred route of administra-
tion is by metered-dose inhaler.
Oxygen therapy. Oxygen will be administered on a
long-term basis to maintain the arterial oxygen satura-
tion at 90% or higher during activities of daily living.
Immunization. Influenza immunization and pneumo-
coccal vaccination are to be used in accord with guide-
lines of the Centers for Disease Control.
Additional measures. Additional measures will be
tailored to individual needs. These may include bron-
chodilators such as theophylline administered orally,
corticosteroids by inhalation or orally, and antibiotics
for treatment of respiratory infections.
Pulmonary rehabilitation. The rehabilitation pro-
gram in NETT is designed to optimize the ability of the
patient to perform the activities of daily living and to
understand and manage the chronic disease. For partic-
ipants undergoing medical therapy alone, the goal of
the NETT rehabilitation program is to optimize exer-
cise capacity. For participants undergoing medical ther-
apy plus LVRS, the goals are to achieve as much phys-
Table I. Evaluation and screening for NETT enrollees
1. Initial screening: review of data and confirmation of coverage by 
a NETT participating center 
2. Consent 1: consent to screening and inclusion in registry; 
understanding of trial design
3. Assessment of eligibility 
4. Completion of pre-rehabilitation assessment: exercise test, oxygen 
titration, 6-minute walk, quality of life instruments, substudy 
testing
5. Determination of study eligibility; also Consent 2: consent to 
participate in pulmonary rehabilitation
6. Pulmonary rehabilitation: 6-10 weeks of supervised pulmonary 
rehabilitation, attendance requirements
7. Post-rehabilitation assessment: see Table II
8. Review of eligibility: if eligible, then perfusion scan and 
pulmonary mechanics
9. Consent 3: Consent to randomization and follow-up
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ical fitness as possible before the operation to effect
early postoperative mobilization and to provide a base-
line of optimized preoperative exercise capacity for
comparison with the postoperative exercise capacity.
All participants will engage in pulmonary rehabilita-
tion, which will be conducted in 3 phases: pre-random-
ization (16-20 sessions over 6-10 weeks); post-ran-
domization (10 sessions over 8-9 weeks); and
long-term maintenance (duration of the trial). The reha-
bilitation programs will be supervised by a NETT clin-
ical center; portions of the program may be carried out
at a NETT-certified rehabilitation facility closer to the
participant’s home. The long-term maintenance pro-
gram will be conducted at home or at a fitness center
with continued monitoring by a NETT clinical center.
Components of the pulmonary rehabilitation program
include the following:
• Comprehensive evaluation of medical, psychosocial,
and nutritional needs
• Setting of goals for education and exercise training
• Exercise training (lower extremity, flexibility,
strengthening, and upper extremity)
• Education about emphysema, medical treatments,
and NETT
• Psychosocial counseling
• Nutritional counseling
Surgical treatment. On the basis of the consensus
that excision of lung tissue at LVRS is more effective
than laser ablation or lung plication in relieving symp-
toms and improving pulmonary function, and to ensure
consistency among participating centers, only stapled
LVRS with excision will be used in the trial. In addi-
tion, all patients treated surgically will undergo bilater-
al LVRS because of the evidence that the bilateral pro-
cedure affords greater and more consistent benefits
than do unilateral operations. 
The surgical approach will not be uniform at all the
centers: 8 of the 17 centers will perform the operation
via median sternotomy, 3 will use bilateral VATS pro-
cedures, and 6 will randomize patients to either medi-
an sternotomy or VATS. Patients will be scheduled for
surgery within 2 weeks of randomization. If exacerba-
tion of their underlying disease or other illness causes
delay beyond this limit, surgery will be postponed
until after the acute illness has subsided. Further pul-
monary rehabilitation and additional testing may be
required to ensure that candidates continue to satisfy
inclusion criteria.
Table II. Trial outcomes assessment
Quality of life/symptoms St George’s Respiratory Questionnaire; Medical Outcomes Study 36-Item Short Form; Quality of Well-Being Scale; 
University of California, San Diego Shortness of Breath Questionnaire; modified Borg Scale for perceived dyspnea
Pulmonary function Spirometry, lung volumes, arterial blood gases, inspiratory and expiratory mouth pressures, oxygen titration
Exercise Cycle ergometry exercise tolerance test, 6-minute walk
General medical History, physical examination
Table III. Inclusion criteria (patients must meet all criteria to participate)
History and physical examination Consistent with emphysema; BMI ≤ 31.1 kg/m2 (men) or ≤ 32.3 kg/m2 (women) at randomization; stable 
on ≤ 20 mg prednisone (or equivalent) daily
Radiographic HRCT scan evidence of bilateral emphysema
Pulmonary function (pre-rehabilitation) FEV1 ≤ 45% predicted (‡ 15% predicted if ‡ 70 years); TLC ‡ 100% predicted; RV ‡ 150% predicted
Arterial blood gas (pre-rehabilitation) PCO2 ≤ 60 mm Hg (Denver: PCO2 ≤ 55 mm Hg); PO2 ‡ 45 mm Hg (Denver: PO2 ‡ 30 mm Hg) on room air
Cardiac assessment Approval for surgery before randomization by cardiologist if any of the following are present: unstable 
angina; LVEF cannot be estimated from the echocardiogram; LVEF < 45%; dobutamine-radionuclide 
cardiac scan indicates coronary artery disease or ventricular dysfunction; arrhythmia (>5 PVCs per minute;
cardiac rhythm other than sinus; PACs at rest)
Surgical assessment Approval for surgery by pulmonary physician, thoracic surgeon, and anesthesiologist after rehabilitation and 
before randomization
Exercise Post-rehabilitation 6-minute walk ‡ 140 meters; able to complete 3 minutes of unloaded pedaling in exercise 
tolerance test (before and after rehabilitation)
Consent Signed consent forms for screening, rehabilitation, and randomization
Smoking Plasma cotinine ≤ 13.7 ng/mL (or arterial carboxyhemoglobin ≤ 2.5% if using nicotine products); 
nonsmoking for 4 months before initial interview and throughout screening
Rehabilitation Must complete pre-randomization assessments, rehabilitation program, and all post-rehabilitation and 
randomization assessments
BMI, Body mass index; FEV1, forced expiratory volume in 1 second; HRCT, high resolution computed tomography; LVEF, left ventricular ejection fraction; PAC,
premature atrial contraction; PVC, premature ventricular contraction; RV, residual volume; TLC, total lung capacity.
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The surgical procedure is directed at excising func-
tionally useless lung tissue. The areas to be resected are
identified by preoperative computed tomographic
images and perfusion scans. On the basis of published
experience, most patients can be expected to have het-
erogenous disease that is most severe in the upper
lobes; in relatively few, emphysema will predominate
in the lower lobes. The surgical procedure entails
removal of approximately 25% to 30% of the total lung
tissue from each side. Surgeons are permitted to rein-
force the staple lines with buttress material to minimize
the incidence and severity of air leaks. Removed tissue
will be weighed and portions will be stored for possi-
ble future studies. For each patient, details of the oper-
ation will be recorded, with special attention paid to the
extent of adhesions, intraoperative difficulties, and
problems with intraoperative hemodynamics.
Intraoperative anesthetic management has been stan-
dardized. Preoperatively, in patients undergoing medi-
an sternotomy, thoracic epidural catheters will be
placed for intraoperative and postoperative pain con-
trol. Extubation within 2 hours is expected either in the
operating room or in the recovery area. Patients will be
admitted either to the intensive care unit or to another
designated unit in line with the standard of care for
patients undergoing major thoracic procedures at the
respective institution. Starting on the first postoperative
day, patients will receive vigorous chest respiratory
therapy and physical therapy to enhance mobilization.
On the basis of previous experience, the most signif-
icant postoperative complication is expected to be air
leaks that last longer than 7 days. This problem is like-
ly to affect up to 40% of surgical patients regardless of
the technique used for LVRS. Other significant compli-
cations to be anticipated include respiratory failure,
especially if re-intubation is necessary, cardiac arrhyth-
mia, and gastrointestinal complications.
Individual centers may choose to discharge patients
with air leaks controlled by the use of Heimlich valves
on the chest tube(s). The date of discharge from the sur-
gical facility, as well as the disposition of the patient
(eg, home, another in-patient facility), will be recorded.
Statistical considerations 
This study is an unmasked, randomized, clinical trial
with a prospectively accrued registry of patients. The
trial consists of an equal allocation of prospectively
randomized patients who receive medical therapy alone
or medical therapy and LVRS. The primary statistical
objectives of the randomized trial are to estimate dif-
ferences between the 2 groups in survival and maxi-
mum exercise capacity.
The primary treatment comparisons will be between
medical therapy and LVRS of either type (median ster-
notomy or VATS). However, the structure and size of
the trial will also permit important subset analyses to
be conducted, as well as comparisons of morbidity,
mortality, and other outcomes within the surgery
group. These differences will be assessed with lower
power than the primary comparison but should permit
clinically important differences to be detected. An
important objective of the trial is to gather information
to characterize any subset of patients who might
receive disproportionate benefit (or risk) from the sur-
gical procedure.
Power and sample size. This trial is designed pri-
Table IV. Exclusionary criteria (presence of any criterion makes the patient ineligible)
Previous operation Lung transplant; LVRS; median sternotomy or lobectomy
Cardiovascular Arrhythmia that might pose a risk during exercise or training; resting bradycardia (<50 beats/min); frequent 
multifocal PVCs; complex ventricular arrhythmia; sustained SVT; history of exercise-related syncope; MI within 
6 months and LVEF < 45%; congestive heart failure within 6 months and LVEF < 45%; uncontrolled hypertension 
(systolic > 200 mm Hg, diastolic > 110 mm Hg)
Pulmonary History of recurrent infections with clinically significant sputum production; pleural or interstitial disease that 
precludes surgery; clinically significant bronchiectasis; pulmonary nodule necessitating surgery; giant bulla 
(greater than one third the volume of the lung); pulmonary hypertension: peak systolic PPA ‡ 45 mm Hg 
(‡ 50 mm Hg in Denver) or mean PPA ‡ 35 mm Hg (‡ 38 mm Hg in Denver); (right heart catheterization is required 
to rule out pulmonary hypertension if peak systolic PPA on echocardiogram ‡ 45 mm Hg); requirement for > 6 L 
oxygen to keep saturation 90% or greater with exercise
Radiographic CT evidence for diffuse emphysema judged unsuitable for LVRS
General Unplanned weight loss of > 10% usual weight in 90 days before enrollment; evidence of systemic disease or 
neoplasia expected to compromise survival during 5-year period; 6-minute walk distance ≤ 140 meters after 
rehabilitation; any disease or condition that interferes with completion of initial or follow-up assessments; 
unwillingness or inability to complete screening or baseline data collection procedures
CT, Computed tomography; LVEF, left ventricular ejection fraction; LVRS, lung volume reduction surgery; MI, myocardial infarction; PPA, pulmonary artery pres-
sure; PVC, premature ventricular contraction; SVT, supraventricular tachycardia.
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marily to determine the difference in survival between
the medical therapy and LVRS groups. The required
sample size has been calculated to be 2500 patients,
that is, 1250 per group.41 The accrual rate required to
reach the target of 2500 patients in 4.5 years is 2.7
patients per clinic per month. Overall, the trial will
have high power to meet other objectives such as
detecting a difference in maximum exercise capacity
(or other continuously distributed random variables).
Analyses. In the initial analysis for any variable,
patients will be counted in the treatment group to which
they were randomly assigned without regard to drop-
outs, drop-ins, or course of therapy (intention-to-treat
principle). All events occurring from randomization on
will be counted in the treatment group to which the
patient was randomly assigned. Analyses will be con-
ducted to assess whether any observed treatment effect
is consistent across subsets of patients (defined by
baseline characteristics, eg, age, race, sex). Analyses
will be conducted separately in the prospectively
defined subset of patients who are thought most likely
to benefit. This approach will be taken for analyses of
mortality, complications, and functional outcomes.
Attempts will be made to define a subset of patients
who benefit from treatment (either LVRS or medical
therapy). Benefit will be defined objectively by a quan-
titative algorithm based on functional capacity, and all
patients will be classified accordingly. The association
between benefit and baseline prognostic factors will be
assessed with the use of a multiple logistic regression
model. The model will be built on a random subset of
patients (50%) and validated on the remaining patients.
The sensitivity and specificity of the “best” such model
will be calculated from the logistic classification
method by means of standard methods. A similar pro-
cedure will be used to identify subsets of patients who
may be at high short-term risk from treatment. These
analyses will be conducted separately in medical and
surgical patients, as well as in the combined group.
Patient rights and responsibilities
Consent process. Three separate consent forms are
used. The first, “Consent for Screening and Patient
Registry,” is to be signed at the first visit at the NETT
clinic, after review of records provided by the patient’s
private physician indicates that the patient is likely to
have emphysema and may be eligible. The second con-
sent statement, “Consent for Pulmonary Rehabilita-
tion,” is to be signed after the patient has completed the
diagnostic and pre-rehabilitation assessments and has
been judged eligible to enroll in the 6- to 10-week pul-
monary rehabilitation program that is required before
assessment for randomization in NETT is undertaken.
The third consent statement, “Consent for Randomiza-
tion,” is to be signed after the patient has completed the
6 to 10 weeks of rehabilitation and the post-rehabilita-
tion assessments and is found to be eligible for ran-
domization, including judgment by the treatment team
that the patient is suitable for surgery. Surgical consent
will be obtained by a separate consent statement pre-
pared and administered by each clinic individually and
will be required only for patients assigned to LVRS. 
Participation in NETT and impact on participa-
tion in the transplant program. Participation in the
trial does not preclude a patient from undergoing lung
transplantation or remaining on the active list.
Although individual patients may be asked by the
NETT staff to consider delaying transplantation at cer-
tain times during the protocol, the final choice will be
made by the patient in consultation with his or her pri-
vate physician and will be directed by his or her clini-
cal situation.
Conclusion
The NETT is a multicenter randomized trial designed
to assess the effect of LVRS compared with medical
therapy on survival and exercise capacity in patients
with severe emphysema. This trial will provide infor-
mation on the role of LVRS in the management of
emphysema, define the characteristics of which
patients, if any, are likely to benefit from LVRS, and
serve as a basis for an HCFA decision on reimburse-
ment for LVRS.
The NETT represents a novel paradigm for evaluat-
ing new medical and surgical treatments. The agree-
ment between NHLBI and HCFA to co-sponsor NETT
specifies for NHLBI to provide scientific and adminis-
trative leadership and monitoring (and associated
costs) and for HCFA to bear the costs of the clinical
services associated with the protocol. AHCPR con-
tributes support for the cost effectiveness analysis.
NETT could serve as a model for evaluating the bene-
fit and appropriate use of new therapies.
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Marvin Pomerantz, MD; Cynthia Raymond, MS; Beth
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Ohio State University, Columbus, Ohio: Philip Diaz, MD
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